{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:46:26Z","timestamp":1753890386673,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Eosinophilic chronic rhinosinusitis (ECRS) is an intractable type 2 inflammatory disease of the paranasal sinuses that persists even after endoscopic sinus surgery (ESS) and systemic corticosteroid therapy. Dupilumab, a monoclonal antibody against the shared receptor components of interleukin (IL)-4 and IL-13, is a novel and effective treatment option for ECRS. Herein, an atypical case of ECRS that improved after infection with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) during dupilumab therapy is reported. A 40-year-old man with a history of ESS for ECRS visited our hospital with complaints of nasal congestion and dysosmia. Nasal endoscopy revealed bilateral nasal polyps occupying the nasal cavity. Computed tomography (CT) revealed a soft tissue density lesion filling all sinuses on both sides. Based on these findings, ECRS recurrence was confirmed; however, 3 years of subsequent corticosteroid therapy did not improve disease activity. Accordingly, dupilumab therapy was initiated, although 6 months of therapy resulted in only slight improvement in ECRS. Eight months after the initiation of dupilumab therapy, the patient was infected with SARS-CoV-2; thereafter, he noticed an improvement in smell. Nasal endoscopy and sinus CT revealed a marked reduction in nasal polyps and soft tissue density lesions of the sinuses, respectively. With continued dupilumab therapy, no re-exacerbation of ECRS was confirmed at the 6-month follow-up from SARS-CoV-2 infection. Currently, there are no reports describing the impact of SARS-CoV-2 infection on ECRS. As such, careful follow-up and accumulation of cases are necessary.<\/jats:p>","DOI":"10.3389\/falgy.2023.1053777","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:48:07Z","timestamp":1675320487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement of eosinophilic chronic rhinosinusitis after infection with severe acute respiratory syndrome corona virus 2 during dupilumab therapy: A case report"],"prefix":"10.3389","volume":"4","author":[{"given":"Mariko","family":"Koike-Ieki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Kagoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Toma-Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sasajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.anai.2014.09.017","article-title":"Correlation of basophil infiltration in nasal polyps with the severity of chronic rhinosinusitis","volume":"114","author":"Kagoya","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaci.2013.02.003","article-title":"Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps","volume":"132","author":"Takabayashi","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.anai.2020.08.001","article-title":"Group 2 innate lymphoid cells in nasal polyposis","volume":"126","author":"Stevens","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/all.14627","article-title":"A murine model of eosinophilic chronic rhinosinusitis using the topical application of a vitamin D3 analog","volume":"76","author":"Kagoya","year":"2021","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s10875-020-00949-6","article-title":"Cytokine profiles before and after immune modulation in hospitalized patients with COVID-19","volume":"41","author":"Azmy","year":"2021","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.otohns.2006.09.014","article-title":"Rhinosinusitis: developing guidance for clinical trials","volume":"135","author":"Meltzer","year":"2006","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B11","first-page":"183","article-title":"Staging in rhinosinusitus","volume":"31","author":"Lund","year":"1993","journal-title":"Rhinology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.anl.2010.05.013","article-title":"Clinical availability of a self-administered odor questionnaire for patients with olfactory disorders","volume":"38","author":"Takebayashi","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"B13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"B14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/jpm12060897","article-title":"Survey on use of local and systemic corticosteroids in the management of chronic rhinosinusitis with nasal polyps: identification of unmet clinical needs","volume":"12","author":"De Corso","year":"2022","journal-title":"J Pers Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jaip.2022.02.026","article-title":"Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases","volume":"10","author":"Canonica","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/v14010147","article-title":"IFN-\u03b3 attenuates eosinophilic inflammation but is not essential for protection against RSV-enhanced asthmatic comorbidity in adult mice","volume":"14","author":"Muralidharan","year":"2022","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1111\/jdv.17913","article-title":"Clinical improvement of atopic dermatitis in two patients co-affected with non-severe COVID-19 infection: a case series and review of literature","volume":"36","author":"Licata","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaip.2022.03.003","article-title":"Chronic rhinosinusitis and COVID-19","volume":"10","author":"Marin","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1038\/s41598-022-09731-7","article-title":"Prolonged and extended impacts of SARS-CoV-2 on the olfactory neurocircuit","volume":"12","author":"Kishimoto-Urata","year":"2022","journal-title":"Sci Rep"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1053777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:48:11Z","timestamp":1675320491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1053777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":20,"alternative-id":["10.3389\/falgy.2023.1053777"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2023.1053777","relation":{},"ISSN":["2673-6101"],"issn-type":[{"type":"electronic","value":"2673-6101"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"1053777"}}